Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fulcrum Therapeutics (FULC) Receivables (2020 - 2022)

Historic Receivables for Fulcrum Therapeutics (FULC) over the last 5 years, with Q4 2024 value amounting to $2.1 million.

  • Fulcrum Therapeutics' Receivables rose 29031.66% to $2.1 million in Q4 2024 from the same period last year, while for Dec 2024 it was $2.1 million, marking a year-over-year increase of 29031.66%. This contributed to the annual value of $2.1 million for FY2024, which is 29031.66% up from last year.
  • Latest data reveals that Fulcrum Therapeutics reported Receivables of $2.1 million as of Q4 2024, which was up 29031.66% from $537000.0 recorded in Q4 2023.
  • Fulcrum Therapeutics' 5-year Receivables high stood at $3.6 million for Q4 2021, and its period low was $229000.0 during Q4 2022.
  • In the last 5 years, Fulcrum Therapeutics' Receivables had a median value of $802500.0 in 2022 and averaged $1.3 million.
  • Its Receivables has fluctuated over the past 5 years, first tumbled by 9370.36% in 2022, then soared by 29031.66% in 2024.
  • Fulcrum Therapeutics' Receivables (Quarter) stood at $2.5 million in 2020, then surged by 43.7% to $3.6 million in 2021, then crashed by 93.7% to $229000.0 in 2022, then skyrocketed by 134.5% to $537000.0 in 2023, then surged by 290.32% to $2.1 million in 2024.
  • Its Receivables stands at $2.1 million for Q4 2024, versus $537000.0 for Q4 2023 and $580000.0 for Q3 2023.